Round 1 Winners!
Proof of Usefulness Report

NEXTBio Capital

Analysis completed on 3/18/2026

+96
Proof of Usefulness Score
You're In Business

The project submits highly exaggerated and unverifiable claims ('everyone' as the target audience, 'most people have used my product'). While the biotech ML sector has strong market relevance, the contradictory metrics (such as a $2.5M all-time market cap for an investment fund claiming 30 team members) and overall poor submission quality indicate extremely low verifiable traction.

Ready to Compete for $150k+ in Prizes?

Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes

View All Reports

Score Breakdown

Real World Utility+37.5
Audience Reach Impact+5.0
Technical Innovation+15.0
Evidence Of Traction+2.5
Market Timing Relevance+40.0
Functional Completeness+1.25
Subtotal+101.25
Usefulness Multiplierx0.95
Final Score+96

Project Details

Description
NEXTBio Capital is an investment firm specializing in biotech and related sectors. Focused on small- and mid-cap biotech companies, we leverage advanced data analytics and machine learning to identify clinical-stage drugs with the highest potential. Founded by seasoned biotech investors with over 40 years of combined experience, NEXTBio Capital is dedicated to fostering long-term partnerships and supporting breakthrough medical advancements.

Algorithm Insights

Market Position
Growing utility with room for optimization
User Engagement
Documented reach suggests active user community
Technical Stack
Modern tech stack aligned with sponsor technologies

Recommendations to Increase Usefulness Score

Document User Growth

Provide specific metrics on user acquisition and retention rates

Showcase Revenue Model

Detail sustainable monetization strategy and current revenue streams

Expand Evidence Base

Include testimonials, case studies, and third-party validation

Technical Roadmap

Share development milestones and feature completion timeline